EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Guselkumab treatment normalizes the stratum corneum ceramide profile and alleviates barrier dysfunction in psoriasis: results of a randomized controlled trial

Jannik Rousel, Catherine Mergen, Menthe E Bergmans, Lisa J Bruijnincx, Marieke L de Kam, Naomi B Klarenbeek, Tessa Niemeyer-van der Kolk, Martijn B A van Doorn, Joke A Bouwstra, Robert Rissmann, Next-Generation ImmunoDermatology Consortium (NGID)

Journal of Lipid Research · 2024-08 · 65 (8) · 100591

DOI: 10.1016/j.jlr.2024.100591 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Lipid Research, 2024-08. Verfasst von Jannik Rousel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, The Netherlands; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Psoriasis, Ceramides, Antibodies, Monoclonal, Humanized, Epidermis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The epidermal inflammation associated with psoriasis drives skin barrier perturbations. The skin barrier is primarily located in stratum corneum (SC). Its function depends on the SC lipid matrix of which ceramides constitute important components. Changes in the ceramide profile directly correlate to barrier function. In this study, we characterized the dynamics of the barrier function and ceramide profile of psoriatic skin during anti-Interleukin-23 therapy with guselkumab. We conducted a double-blind, randomized controlled trial in which 26 mild-to-severe plaque psoriasis patients were randomization 3:1-100 mg guselkumab or placebo for 16 weeks and barrier dynamics monitored throughout. Barrier function was measured by trans-epidermal water loss measurements. Untargeted ceramide profiling was performed using liquid chromatography-mass spectrometry after SC was harvested using tape-stripping. The barrier function and ceramide profile of lesional skin normalized to that of controls during treatment with guselkumab, but not placebo. This resulted in significant differences compared to placebo at the end of the treatment. Changes in the lesional ceramide profile during treatment correlated with barrier function and target lesion severity. Nonlesional skin remained similar throughout treatment. Guselkumab therapy restored the skin barrier in psoriasis. Concomitant correlations between skin barrier function, the ceramide profile, and disease severity demonstrate their interdependency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisCeramidesAntibodies, Monoclonal, HumanizedEpidermisHumansMaleFemaleMiddle AgedAdultDouble-Blind Method

Stichwörter der Autor:innen

BarrierCeramidesClinical trialsLipidomicsPsoriasisSkinStratum Corneum

Substanzen

CeramidesguselkumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Centre for Human Drug Research, Leiden, The Netherlands; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
  • Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
  • Centre for Human Drug Research, Leiden, The Netherlands; Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Centre for Human Drug Research, Leiden, The Netherlands.
  • Centre for Human Drug Research, Leiden, The Netherlands; Department of Dermatology, Erasmus Medical Centre, Rotterdam, The Netherlands.
  • Centre for Human Drug Research, Leiden, The Netherlands; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Department of Dermatology, Leiden University Medical Center, Leiden, The Net…

Zitieren

APA

Rousel, J., Mergen, C., Bergmans, M. E., Bruijnincx, L. J., de Kam, M. L., Klarenbeek, N. B., Niemeyer-van der Kolk, T., van Doorn, M. B. A., Bouwstra, J. A., Rissmann, R., & Next-Generation ImmunoDermatology Consortium (NGID) (2024). Guselkumab treatment normalizes the stratum corneum ceramide profile and alleviates barrier dysfunction in psoriasis: results of a randomized controlled trial. Journal of Lipid Research, 65(8), 100591. https://doi.org/10.1016/j.jlr.2024.100591

Vancouver

Rousel J, Mergen C, Bergmans ME, Bruijnincx LJ, de Kam ML, Klarenbeek NB, et al. Guselkumab treatment normalizes the stratum corneum ceramide profile and alleviates barrier dysfunction in psoriasis: results of a randomized controlled trial. Journal of Lipid Research. 2024;65(8):100591. doi:10.1016/j.jlr.2024.100591

BibTeX
@article{Rousel2024,
  author = {Rousel, Jannik and Mergen, Catherine and Bergmans, Menthe E and Bruijnincx, Lisa J and de Kam, Marieke L and Klarenbeek, Naomi B and Niemeyer-van der Kolk, Tessa and van Doorn, Martijn B A and Bouwstra, Joke A and Rissmann, Robert and Next-Generation ImmunoDermatology Consortium (NGID), Next-Generation ImmunoDermatology Consortium (NGID)},
  title = {Guselkumab treatment normalizes the stratum corneum ceramide profile and alleviates barrier dysfunction in psoriasis: results of a randomized controlled trial},
  journal = {Journal of Lipid Research},
  year = {2024},
  volume = {65},
  number = {8},
  pages = {100591},
  doi = {10.1016/j.jlr.2024.100591}
}
Kostenlos starten →